One-year clinical follow-up with the serpentine balloon expandable stent
| Autor: | Ariel Roguin, Rafael Beyar, Jamal Hir, Benjamin Peled, Ehud Grenadier, Shai Linn, Luis Gruberg, Walter Markiewicz, Iris Eisen |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Target lesion medicine.medical_specialty medicine.medical_treatment Biocompatible Materials Coronary Disease Coronary Angiography Disease-Free Survival Prosthesis Implantation Coronary artery disease Restenosis Recurrence medicine Humans Myocardial infarction Angioplasty Balloon Coronary Survival rate Retrospective Studies business.industry Stent General Medicine Middle Aged Stainless Steel medicine.disease Thrombosis Survival Rate Treatment Outcome Bypass surgery Female Stents Radiology Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0954-6928 |
| DOI: | 10.1097/00019501-199909000-00012 |
| Popis: | BACKGROUND We recently reported a high technical and 30-day clinical success rate among the first 100 patients treated with the tubular, serpentine design, stainless steel, balloon-expandable stent (beStent) in Israel. The present study examined the clinical results in these patients after the first year. METHODS Seventy-eight men and 22 women were included in the study. Previous myocardial infarction, bypass surgery and percutaneous transluminal coronary angioplasty had occurred in 52%, 12% and 26% of the patients, respectively. Diabetes mellitus was present in 30 patients and hypertension in 34 patients. One hundred and forty-eight stents of 15, 25, and 35 mm lengths were used. The indications for stenting were suboptimal results (n = 85), bailout conditions (n = 10) or for the prevention of restenosis (n = 8), and lesion types were A (n = 10), B1 (n = 29), B2 (n = 20), and C (n = 44). All patients were clinically monitored with regular visits at 1, 3, 6, 9 and 12 months. RESULTS Overall, the 12-month event-free survival rate was 82%. Subacute thrombosis occurred in two patients. There were two non-cardiac deaths, one O-wave myocardial infarction, six elective bypass surgeries and 12 target lesion revascularizations. Event-free survival was significantly higher for those with lesions shorter than 15 mm than for those with lesions longer than 15 mm (90% versus 67%, P = 0.003), and for women compared with men (96% versus 78%, P = 0.02). CONCLUSIONS The initial experience with the beStent shows favorable long-term results with an overall event rate of 18% for this subset of relatively complex lesions; higher event rates were observed for longer lesions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|